Skip Navigation
Skip to contents

JMD : Journal of Movement Disorders

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
6 "Hui-Jun Yang"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Brief communications
Evaluating the validity and reliability of the Korean version of Scales for Outcomes in Parkinson’s Disease–Cognition
Jinse Park, Eung Seok Oh, Seong-Beom Koh, In-Uk Song, Tae-Beom Ahn, Sang Jin Kim, Sang-Myung Cheon, Yun Joong Kim, Jin Whan Cho, Hyeo-Il Ma, Mee-Young Park, Jong Sam Baik, Phil Hyu Lee, Sun Ju Chung, Jong-Min Kim, Han-Joon Kim, Young-Hee Sung, Do Young Kwon, Jae-Hyeok Lee, Jee-Young Lee, Ji Sun Kim, Ji Young Yun, Hee Jin Kim, Jin Young Hong, Mi-Jung Kim, Jinyoung Youn, Ji Seon Kim, Hui-Jun Yang, Won Tae Yoon, Sooyeoun You, Kyum-Yil Kwon, Su-Yun Lee, Younsoo Kim, Hee-Tae Kim, Joong-Seok Kim, Ji-Young Kim
Received March 8, 2024  Accepted April 2, 2024  Published online April 3, 2024  
DOI: https://doi.org/10.14802/jmd.24061    [Accepted]
  • 355 View
  • 14 Download
AbstractAbstract PDF
Objective
The Scales for Outcomes in Parkinson’s Disease–Cognition (SCOPA-Cog) was developed to screen for cognition in PD. In this study, we aimed to evaluate the validity and reliability of the Korean version of the SCOPA-cog.
Methods
We recruited 129 PD patients from 31 clinics with movement disorders in South Korea. The original version of the SCOPA-cognition was translated into Korean using the translation-retranslation method. The test-rest method with an intraclass correlation coefficient (ICC) and Cronbach’s alpha coefficient were used to assess reliability. The Spearman’s Rank correlation analysis with Montreal Cognitive Assessment-Korean version (MOCA-K) and Korean Mini-Mental State Examination (K-MMSE) were used to assess concurrent validity.
Results
The Cronbach’s alpha coefficient was 0.797, and the ICC was 0.887. Spearman’s rank correlation analysis showed a significant correlation with the K-MMSE and MOCA-K scores (r = 0.546 and r = 0.683, respectively).
Conclusions
Our results demonstrate that K-SCOPA-Cog exhibits good reliability and validity.
A Survey of Perspectives on Telemedicine for Patients With Parkinson’s Disease
Jae Young Joo, Ji Young Yun, Young Eun Kim, Yu Jin Jung, Ryul Kim, Hui-Jun Yang, Woong-Woo Lee, Aryun Kim, Han-Joon Kim
J Mov Disord. 2024;17(1):89-93.   Published online August 22, 2023
DOI: https://doi.org/10.14802/jmd.23130
  • 1,296 View
  • 123 Download
AbstractAbstract PDFSupplementary Material
Objective
Parkinson’s disease (PD) patients often find it difficult to visit hospitals because of motor symptoms, distance to the hospital, or the absence of caregivers. Telemedicine is one way to solve this problem.
Methods
We surveyed 554 PD patients from eight university hospitals in Korea. The questionnaire consisted of the clinical characteristics of the participants, possible teleconferencing methods, and preferences for telemedicine.
Results
A total of 385 patients (70%) expressed interest in receiving telemedicine. Among them, 174 preferred telemedicine whereas 211 preferred in-person visits. The longer the duration of disease, and the longer the time required to visit the hospital, the more patients were interested in receiving telemedicine.
Conclusion
This is the first study on PD patients’ preferences regarding telemedicine in Korea. Although the majority of patients with PD have a positive view of telemedicine, their interest in receiving telemedicine depends on their different circumstances.
Original Articles
Musculoskeletal Problems Affect the Quality of Life of Patients with Parkinson’s Disease
Young Eun Kim, Han-Joon Kim, Ji Young Yun, Woong-Woo Lee, Hui-Jun Yang, Jong-Min Kim, Beomseok Jeon
J Mov Disord. 2018;11(3):133-138.   Published online September 30, 2018
DOI: https://doi.org/10.14802/jmd.18022
  • 8,106 View
  • 148 Download
  • 10 Web of Science
  • 9 Crossref
AbstractAbstract PDF
Objective
Musculoskeletal problems are more common in patients with Parkinson’s disease (PD) than in normal elderly, but the impact of musculoskeletal problems on health-related quality of life (HRQoL) in patients with PD is unknown.
Methods
Four hundred consecutive patients with PD were enrolled for the evaluation of musculoskeletal problems and HRQoL. HRQoL was assessed by the 36-Item Short Form Health Survey, which comprised physical health and mental health.
Results
Of the total patients, 265 patients had musculoskeletal problems, and 135 patients did not have musculoskeletal problems. Patients with musculoskeletal problems reported lower levels of HRQoL in terms of physical health than did patients without musculoskeletal problems (p < 0.05). In women, all components of physical health were lower in patients with musculoskeletal problems than in patients without musculoskeletal problems (p < 0.05). Meanwhile, in men, only the bodily pain score of physical health was lower in patients with musculoskeletal problems than in patients without musculoskeletal problems. Mental health and physical health were negatively correlated with depression, Unified Parkinson’s Disease Rating Scale I & II scores, and pain severity from musculoskeletal problems, in that order (p < 0.01 for all).
Conclusion
These results suggest that musculoskeletal problems in patients with PD affect HRQoL significantly, mainly in terms of physical health rather than mental health and especially in women rather than men. Musculoskeletal problems should not be overlooked in the care of patients with PD.

Citations

Citations to this article as recorded by  
  • Total knee arthroplasty in patients with Parkinson’s disease: A systematic review and meta-analysis protocol
    Guangchen Sun, Hui Yu, Jun Cui, Ming Li, Yuefang Ru
    Medicine.2022; 101(52): e32315.     CrossRef
  • Quality of life of older adults in two contrasting neighbourhoods in Accra, Ghana
    Dominic A. Alaazi, Devidas Menon, Tania Stafinski, Stephen Hodgins, Gian Jhangri
    Social Science & Medicine.2021; 270: 113659.     CrossRef
  • The Efficiency of Spa Rehabilitation in Chronic Ischemic Stroke Patients—Preliminary Reports
    Bogumiła Pniak, Justyna Leszczak, Jadwiga Kurczab, Aleksandra Krzemińska, Joanna Pięta, Agnieszka Plis, Ewelina Czenczek-Lewandowska, Agnieszka Guzik
    Brain Sciences.2021; 11(4): 501.     CrossRef
  • Sex-specific effects of subthalamic nucleus stimulation on pain in Parkinson’s disease
    Olga Khazen, Marisa DiMarzio, Kelsey Platanitis, Heather C. Grimaudo, Maria Hancu, Miriam M. Shao, Michael D. Staudt, Lucy Maguire, Vishad V. Sukul, Jennifer Durphy, Era K. Hanspal, Octavian Adam, Eric Molho, Julie G. Pilitsis
    Journal of Neurosurgery.2021; 135(2): 629.     CrossRef
  • An overview of pain in Parkinson's disease
    Yi-Cheng Tai, Chin-Hsien Lin
    Clinical Parkinsonism & Related Disorders.2020; 2: 1.     CrossRef
  • Clinical Perspectives of Parkinson's Disease for Ophthalmologists, Otorhinolaryngologists, Cardiologists, Dentists, Gastroenterologists, Urologists, Physiatrists, and Psychiatrists
    Ji-Hyun Choi, Jong-Min Kim, Hee Kyung Yang, Hyo-Jung Lee, Cheol Min Shin, Seong Jin Jeong, Won-Seok Kim, Ji Won Han, In-Young Yoon, Yoo Sung Song, Yun Jung Bae
    Journal of Korean Medical Science.2020;[Epub]     CrossRef
  • Parkinson's Disease Is Associated with Increased Complications, Readmission Rates, and Costs of Care after Total Hip Arthroplasty: A Matched-Cohort Analysis
    Simon Katz, Kevin B. Marchand, Rushabh M. Vakharia, Hiba Anis, Nipun Sodhi, Nicolas S. Piuzzi, Michael A. Mont, Martin W. Roche
    The Journal of Hip Surgery.2020; 4(03): 149.     CrossRef
  • Chronic Pain Treatment Strategies in Parkinson’s Disease
    Amber Edinoff, Niro Sathivadivel, Timothy McBride, Allyson Parker, Chikezie Okeagu, Alan D. Kaye, Adam M. Kaye, Jessica S. Kaye, Rachel J. Kaye, Meeta M. Sheth, Omar Viswanath, Ivan Urits
    Neurology International.2020; 12(3): 61.     CrossRef
  • Sex differences in the short-term and long-term effects of subthalamic nucleus stimulation in Parkinson's disease
    Ryul Kim, Dallah Yoo, Ji-Hyun Choi, Jung Hwan Shin, Sangmin Park, Han-Joon Kim, Sun Ha Paek, Beomseok Jeon
    Parkinsonism & Related Disorders.2019; 68: 73.     CrossRef
Amantadine and the Risk of Dyskinesia in Patients with Early Parkinson’s Disease: An Open-Label, Pragmatic Trial
Aryun Kim, Young Eun Kim, Ji Young Yun, Han-Joon Kim, Hui-Jun Yang, Woong-Woo Lee, Chae Won Shin, Hyeyoung Park, Yu Jin Jung, Ahro Kim, Yoon Kim, Mihee Jang, Beomseok Jeon
J Mov Disord. 2018;11(2):65-71.   Published online May 30, 2018
DOI: https://doi.org/10.14802/jmd.18005
  • 9,310 View
  • 252 Download
  • 11 Web of Science
  • 14 Crossref
AbstractAbstract PDFSupplementary Material
Objective
We examined whether amantadine can prevent the development of dyskinesia.
Methods
Patients with drug-naïve Parkinson’s disease (PD), younger than 70 years of age and in the early stage of PD (Hoehn and Yahr scale < 3), were recruited from April 2011 to December 2014. The exclusion criteria included the previous use of antiparkinsonian medication, the presence of dyskinesia, significant psychological disorders, and previous history of a hypersensitivity reaction. Patients were consecutively assigned to one of 3 treatment groups in an open label fashion: Group A-1, amantadine first and then levodopa when needed; Group A-2, amantadine first, dopamine agonist when needed, and then levodopa; and Group B, dopamine agonist first and then levodopa when needed. The primary endpoint was the development of dyskinesia, which was analyzed by the Kaplan-Meier survival rate.
Results
A total of 80 patients were enrolled: Group A-1 (n = 27), Group A-2 (n = 27), and Group B (n = 26). Twenty-four patients were excluded from the analysis due to the following: withdrawal of amantadine or dopamine agonist (n = 9), alternative diagnosis (n = 2), withdrawal of consent (n = 1), and breach in the protocol (n = 12). After exclusion, 5 of the 56 (8.93%) patients developed dyskinesia. Patients in Group A-1 and A-2 tended to develop dyskinesia less often than those in Group B (cumulative survival rates of 0.933, 0.929, and 0.700 for A-1, A-2, and B, respectively; p = 0.453).
Conclusion
Amantadine as an initial treatment may decrease the incidence of dyskinesia in patients with drug-naïve PD.

Citations

Citations to this article as recorded by  
  • Investigation of the Long-Term Effects of Amantadine Use in Parkinson’s Disease
    Sangmin Park, Jung Hwan Shin, Seung Ho Jeon, Chan Young Lee, Han-Joon Kim, Beomseok Jeon
    Journal of Movement Disorders.2023; 16(2): 224.     CrossRef
  • Polypharmazie bei der Behandlung von Parkinsonsymptomen: eine Nutzen-Risiko Abwägung
    J. Bedarf, I. Csoti, H. Herbst, P. Urban, D. Woitalla, U. Wüllner
    DGNeurologie.2023; 6(6): 504.     CrossRef
  • Role of glutamate receptor complex in the organism. Ligands of NMDA receptors in neurodegenerative processes – a modern state of the problem
    Vladimir D. Dergachev, Ekaterina E. Yakovleva, Eugenii R. Bychkov, Levon B. Piotrovskiy, Petr D. Shabanov
    Reviews on Clinical Pharmacology and Drug Therapy.2022; 20(1): 17.     CrossRef
  • Effect of glycine transporter 1 inhibition with bitopertin on parkinsonism and L-DOPA induced dyskinesia in the 6-OHDA-lesioned rat
    Imane Frouni, Woojin Kang, Dominique Bédard, Sébastien Belliveau, Cynthia Kwan, Shadi Hadj-Youssef, Élodie Bourgeois-Cayer, Leanne Ohlund, Lekha Sleno, Adjia Hamadjida, Philippe Huot
    European Journal of Pharmacology.2022; 929: 175090.     CrossRef
  • Amantadine in the treatment of Parkinson’s disease. New opportunities in the context of COVID-19
    E.A. Katunina
    Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova.2021; 121(4): 101.     CrossRef
  • Current Knowledge on the Background, Pathophysiology and Treatment of Levodopa-Induced Dyskinesia—Literature Review
    Michał Hutny, Jagoda Hofman, Aleksandra Klimkowicz-Mrowiec, Agnieszka Gorzkowska
    Journal of Clinical Medicine.2021; 10(19): 4377.     CrossRef
  • Neuroinflammation and blood–brain barrier disruption following traumatic brain injury: Pathophysiology and potential therapeutic targets
    Suraj Sulhan, Kristopher A. Lyon, Lee A. Shapiro, Jason H. Huang
    Journal of Neuroscience Research.2020; 98(1): 19.     CrossRef
  • Emerging drugs for the treatment of L-DOPA-induced dyskinesia: an update
    Sohaila AlShimemeri, Susan H Fox, Naomi P Visanji
    Expert Opinion on Emerging Drugs.2020; 25(2): 131.     CrossRef
  • Pharmacological Treatment of Early Motor Manifestations of Parkinson Disease (PD)
    Michelle Ann C. Sy, Hubert H. Fernandez
    Neurotherapeutics.2020; 17(4): 1331.     CrossRef
  • Gut Microbiota Approach—A New Strategy to Treat Parkinson’s Disease
    Jing Liu, Fei Xu, Zhiyan Nie, Lei Shao
    Frontiers in Cellular and Infection Microbiology.2020;[Epub]     CrossRef
  • Viewpoint: Developing drugs for levodopa‐induced dyskinesia in PD: Lessons learnt, what does the future hold?
    Susan H. Fox, Jonathan M. Brotchie
    European Journal of Neuroscience.2019; 49(3): 399.     CrossRef
  • Polypharmacy in Parkinson’s disease: risks and benefits with little evidence
    I. Csoti, H. Herbst, P. Urban, D. Woitalla, U. Wüllner
    Journal of Neural Transmission.2019; 126(7): 871.     CrossRef
  • Activation of mGlu2/3 receptors, a novel therapeutic approach to alleviate dyskinesia and psychosis in experimental parkinsonism
    Imane Frouni, Adjia Hamadjida, Cynthia Kwan, Dominique Bédard, Vaidehi Nafade, Fleur Gaudette, Stephen G. Nuara, Jim C. Gourdon, Francis Beaudry, Philippe Huot
    Neuropharmacology.2019; 158: 107725.     CrossRef
  • Can therapeutic strategies prevent and manage dyskinesia in Parkinson’s disease? An update
    Valentina Leta, Peter Jenner, K. Ray Chaudhuri, Angelo Antonini
    Expert Opinion on Drug Safety.2019; 18(12): 1203.     CrossRef
Validation of the Korean Version of the Scale for Outcomes in Parkinson’s Disease-Autonomic
Ji-Young Kim, In-Uk Song, Seong-Beom Koh, Tae-Beom Ahn, Sang Jin Kim, Sang-Myung Cheon, Jin Whan Cho, Yun Joong Kim, Hyeo-Il Ma, Mee-Young Park, Jong Sam Baik, Phil Hyu Lee, Sun Ju Chung, Jong-Min Kim, Han-Joon Kim, Young-Hee Sung, Do Young Kwon, Jae-Hyeok Lee, Jee-Young Lee, Ji Sun Kim, Ji Young Yun, Hee Jin Kim, Jin Young Hong, Mi-Jung Kim, Jinyoung Youn, Ji Seon Kim, Eung Seok Oh, Hui-Jun Yang, Won Tae Yoon, Sooyeoun You, Kyum-Yil Kwon, Hyung-Eun Park, Su-Yun Lee, Younsoo Kim, Hee-Tae Kim, Joong-Seok Kim
J Mov Disord. 2017;10(1):29-34.   Published online January 18, 2017
DOI: https://doi.org/10.14802/jmd.16057
  • 15,191 View
  • 360 Download
  • 29 Web of Science
  • 30 Crossref
AbstractAbstract PDFSupplementary Material
Objective
Autonomic symptoms are commonly observed in patients with Parkinson’s disease (PD) and often limit the activities of daily living. The Scale for Outcomes in Parkinson’s disease-Autonomic (SCOPA-AUT) was developed to evaluate and quantify autonomic symptoms in PD. The goal of this study was to translate the original SCOPA-AUT, which was written in English, into Korean and to evaluate its reliability and validity for Korean PD patients.
Methods
For the translation, the following processes were performed: forward translation, backward translation, expert review, pretest of the pre-final version and development of the final Korean version of SCOPA-AUT (K-SCOPA-AUT). In total, 127 patients with PD from 31 movement disorder clinics of university-affiliated hospitals in Korea were enrolled in this study. All patients were assessed using the K-SCOPA-AUT and other motor, non-motor, and quality of life scores. Test-retest reliability for the K-SCOPA-AUT was assessed over a time interval of 10−14 days.
Results
The internal consistency and reliability of the K-SCOPA-AUT was 0.727 as measured by the mean Cronbach’s α-coefficient. The test-retest correlation reliability was 0.859 by the Guttman split-half coefficient. The total K-SCOPA-AUT score showed a positive correlation with other non-motor symptoms [the Korean version of non-motor symptom scale (K-NMSS)], activities of daily living (Unified Parkinson’s Disease Rating Scale part II) and quality of life [the Korean version of Parkinson’s Disease Quality of Life 39 (K-PDQ39)].
Conclusion
The K-SCOPA-AUT had good reliability and validity for the assessment of autonomic dysfunction in Korean PD patients. Autonomic symptom severities were associated with many other motor and non-motor impairments and influenced quality of life.

Citations

Citations to this article as recorded by  
  • Baseline prevalence and longitudinal assessment of autonomic dysfunction in early Parkinson’s disease
    Lanqing Yang, Huan Gao, Min Ye
    Journal of Neural Transmission.2024; 131(2): 127.     CrossRef
  • Association Between Gait and Dysautonomia in Patients With De Novo Parkinson’s Disease: Forward Gait Versus Backward Gait
    Seon-Min Lee, Mina Lee, Eun Ji Lee, Rae On Kim, Yongduk Kim, Kyum-Yil Kwon
    Journal of Movement Disorders.2023; 16(1): 59.     CrossRef
  • Beyond shallow feelings of complex affect: Non-motor correlates of subjective emotional experience in Parkinson’s disease
    Claudia Carricarte Naranjo, Claudia Sánchez Luaces, Ivonne Pedroso Ibáñez, Andrés Machado, Hichem Sahli, María Antonieta Bobes, Vincenzo De Luca
    PLOS ONE.2023; 18(2): e0281959.     CrossRef
  • Autonomic function and motor subtypes in Parkinson’s disease: a multicentre cross-sectional study
    Si-Chun Gu, Rong Shi, Chen Gao, Xiao-Lei Yuan, You Wu, Zhen-Guo Liu, Chang-De Wang, Shao-Rong Zhao, Xiqun Chen, Can-Xing Yuan, Qing Ye
    Scientific Reports.2023;[Epub]     CrossRef
  • Clinical manifestation of patients with isolated rapid eye movement sleep behavior disorder after modest-to-long disease duration
    Jung Kyung Hong, Jong-Min Kim, Ki-woong Kim, Ji Won Han, Soyeon Ahn, In-Young Yoon
    Sleep.2022;[Epub]     CrossRef
  • Associations of cognitive dysfunction with motor and non-motor symptoms in patients with de novo Parkinson’s disease
    Kyum-Yil Kwon, Suyeon Park, Rae On Kim, Eun Ji Lee, Mina Lee
    Scientific Reports.2022;[Epub]     CrossRef
  • Autonomic dysfunction in Parkinson's disease: Results from the Faroese Parkinson's disease cohort
    Aksel Berg, Sára Bech, Jan Aasly, Matthew J. Farrer, Maria Skaalum Petersen
    Neuroscience Letters.2022; 785: 136789.     CrossRef
  • Prevalence of lower urinary tract symptoms, urinary incontinence and retention in Parkinson's disease: A systematic review and meta-analysis
    Fang-Fei Li, Yu-Sha Cui, Rui Yan, Shuang-Shuang Cao, Tao Feng
    Frontiers in Aging Neuroscience.2022;[Epub]     CrossRef
  • White matter tract-specific microstructural disruption is associated with depressive symptoms in isolated RBD
    Jung-Ick Byun, Seunghwan Oh, Jun-Sang Sunwoo, Jung-Won Shin, Tae-Joon Kim, Jin-Sun Jun, Han-Joon Kim, Won Chul Shin, Joon-Kyung Seong, Ki-Young Jung
    NeuroImage: Clinical.2022; 36: 103186.     CrossRef
  • Comparison of disease progression between brain-predominant Parkinson's disease versus Parkinson's disease with body-involvement phenotypes
    Dong-Woo Ryu, Sang-Won Yoo, Yoon-Sang Oh, Kwang-Soo Lee, Seunggyun Ha, Joong-Seok Kim
    Neurobiology of Disease.2022; 174: 105883.     CrossRef
  • Corneal confocal microscopy differentiates patients with Parkinson’s disease with and without autonomic involvement
    Ning-Ning Che, Shuai Chen, Qiu-Huan Jiang, Si-Yuan Chen, Zhen-Xiang Zhao, Xue Li, Rayaz A. Malik, Jian-Jun Ma, Hong-Qi Yang
    npj Parkinson's Disease.2022;[Epub]     CrossRef
  • Association of Nucleus Basalis of Meynert Functional Connectivity and Cognition in Idiopathic Rapid-Eye-Movement Sleep Behavior Disorder
    Jung-Ick Byun, Kwang Su Cha, Minah Kim, Woo-Jin Lee, Han Sang Lee, Jun-Sang Sunwoo, Jung-Won Shin, Tae-Joon Kim, Jin-Sun Jun, Han-Joon Kim, Won Chul Shin, Carlos H. Schenck, Sang Kun Lee, Ki-Young Jung
    Journal of Clinical Neurology.2022; 18(5): 562.     CrossRef
  • White Matter Tract-Specific Microstructural Disruption is Associated with Depressive Symptoms in Isolated Rbd
    Jung-Ick Byun, Seunghwan Oh, Jun-Sang Sunwoo, Jung-Won Shin, Tae-Joon Kim, Jin-Sun Jun, Han-Joon Kim, Won Chul Shin, Joon-Kyung Seong, Ki-Young Jung
    SSRN Electronic Journal .2022;[Epub]     CrossRef
  • Altered insular functional connectivity in isolated REM sleep behavior disorder: a data-driven functional MRI study
    Jung-Ick Byun, Kwang Su Cha, Minah Kim, Woo-Jin Lee, Han Sang Lee, Jun-Sang Sunwoo, Jung-Won Shin, Tae-Joon Kim, Jangsup Moon, Soon-Tae Lee, Keun-Hwa Jung, Kon Chu, Man-Ho Kim, Han-Joon Kim, Won Chul Shin, Sang Kun Lee, Ki-Young Jung
    Sleep Medicine.2021; 79: 88.     CrossRef
  • Association of fall risk factors and non-motor symptoms in patients with early Parkinson’s disease
    Kyum-Yil Kwon, Suyeon Park, Eun Ji Lee, Mina Lee, Hyunjin Ju
    Scientific Reports.2021;[Epub]     CrossRef
  • Impact of motor subtype on non‐motor symptoms and fall‐related features in patients with early Parkinson's disease
    Kyum‐Yil Kwon, Eun Ji Lee, Mina Lee, Hyunjin Ju, Kayeong Im
    Geriatrics & Gerontology International.2021; 21(5): 416.     CrossRef
  • Extra-basal ganglia iron content and non-motor symptoms in drug-naïve, early Parkinson’s disease
    Minkyeong Kim, Seulki Yoo, Doyeon Kim, Jin Whan Cho, Ji Sun Kim, Jong Hyun Ahn, Jun Kyu Mun, Inyoung Choi, Seung-Kyun Lee, Jinyoung Youn
    Neurological Sciences.2021; 42(12): 5297.     CrossRef
  • Clinical Assessment Scales in Autonomic Nervous System Disorders
    Eun Bin Cho, Ki-Jong Park
    Journal of the Korean Neurological Association.2021; 39(2 Suppl): 60.     CrossRef
  • Cardiac sympathetic burden reflects Parkinson disease burden, regardless of high or low orthostatic blood pressure changes
    Sang-Won Yoo, Joong-Seok Kim, Yoon-Sang Oh, Dong-Woo Ryu, Seunggyun Ha, Ji-Yeon Yoo, Kwang-Soo Lee
    npj Parkinson's Disease.2021;[Epub]     CrossRef
  • Understanding fatigue in progressive supranuclear palsy
    Jong Hyeon Ahn, Joomee Song, Dong Yeong Lee, Jinyoung Youn, Jin Whan Cho
    Scientific Reports.2021;[Epub]     CrossRef
  • Validation of the Korean version of the composite autonomic symptom scale 31 in patients with Parkinson’s disease
    Jong Hyeon Ahn, Jin Myoung Seok, Jongkyu Park, Heejeong Jeong, Younsoo Kim, Joomee Song, Inyoung Choi, Jin Whan Cho, Ju-Hong Min, Byoung Joon Kim, Jinyoung Youn, Antonina Luca
    PLOS ONE.2021; 16(10): e0258897.     CrossRef
  • Cardiac Autonomic Dysfunction Is Associated with Severity of REM Sleep without Atonia in Isolated REM Sleep Behavior Disorder
    Sooyeoun You, Kyoung Sook Won, Keun Tae Kim, Hyang Woon Lee, Yong Won Cho
    Journal of Clinical Medicine.2021; 10(22): 5414.     CrossRef
  • Characteristics of Autonomic Dysfunction in Parkinson’s Disease: A Large Chinese Multicenter Cohort Study
    Zhou Zhou, Xiaoting Zhou, Xiaoxia Zhou, Yaqin Xiang, Liping Zhu, Lixia Qin, Yige Wang, Hongxu Pan, Yuwen Zhao, Qiying Sun, Qian Xu, Xinyin Wu, Xinxiang Yan, Jifeng Guo, Beisha Tang, Zhenhua Liu
    Frontiers in Aging Neuroscience.2021;[Epub]     CrossRef
  • Autonomic Dysfunction in Parkinson's Disease: Results from the Faroese Parkinson's Disease Cohort
    Aksel Kambsskarð Berg, Sára Bech, Jan O. Aasly, Matthew J. Farrer, Maria Skaalum Petersen
    SSRN Electronic Journal .2021;[Epub]     CrossRef
  • Subtypes of Sleep Disturbance in Parkinson's Disease Based on the Cross-Culturally Validated Korean Version of Parkinson's Disease Sleep Scale-2
    Hui-Jun Yang, Han-Joon Kim, Seong-Beom Koh, Joong-Seok Kim, Tae-Beom Ahn, Sang-Myung Cheon, Jin Whan Cho, Yoon-Joong Kim, Hyeo-Il Ma, Mee Young Park, Jong Sam Baik, Phil Hyu Lee, Sun Ju Chung, Jong-Min Kim, In-Uk Song, Ji-Young Kim, Young-Hee Sung, Do You
    Journal of Clinical Neurology.2020; 16(1): 66.     CrossRef
  • Risk Factors for Falls in Patients with de novo Parkinson’s Disease: A Focus on Motor and Non-Motor Symptoms
    Kyum-Yil Kwon, Mina Lee, Hyunjin Ju, Kayeong Im
    Journal of Movement Disorders.2020; 13(2): 142.     CrossRef
  • Peripheral Blood Inflammatory Cytokines in Idiopathic REM Sleep Behavior Disorder
    Ryul Kim, Jin‐Sun Jun, Han‐Joon Kim, Ki‐Young Jung, Yong‐Won Shin, Tae‐Won Yang, Keun Tae Kim, Tae‐Joon Kim, Jung‐Ick Byun, Jun‐Sang Sunwoo, Beomseok Jeon
    Movement Disorders.2019; 34(11): 1739.     CrossRef
  • Urinary Dysfunctions and Post-Void Residual Urine in Typical and Atypical Parkinson Diseases
    Yang-Hyun Lee, Jee-Eun Lee, Dong-Woo Ryu, Yoon-Sang Oh, Kwang-Soo Lee, Sung-Hoo Hong, Joong-Seok Kim
    Journal of Parkinson's Disease.2018; 8(1): 145.     CrossRef
  • Rasch Analysis of the Clinimetric Properties of the Korean Dizziness Handicap Inventory in Patients with Parkinson Disease
    Da-Young Lee, Hui-Jun Yang, Dong-Seok Yang, Jin-Hyuk Choi, Byoung-Soo Park, Ji-Yun Park
    Research in Vestibular Science.2018; 17(4): 152.     CrossRef
  • Clinical Characteristics of Parkinson’s Disease Developed from Essential Tremor
    Dong-Woo Ryu, Si-Hoon Lee, Yoon-Sang Oh, Jae-Young An, Jeong-Wook Park, In-Uk Song, Kwang-Soo Lee, Joong-Seok Kim
    Journal of Parkinson's Disease.2017; 7(2): 369.     CrossRef
Case Report
Amantadine Induced Corneal Edema in a Patient with Primary Progressive Freezing of Gait
Young Eun Kim, Ji Young Yun, Hui-Jun Yang, Han-Joon Kim, Mee Kum Kim, Won Ryang Wee, Beom S. Jeon
J Mov Disord. 2013;6(2):34-36.   Published online October 30, 2013
DOI: https://doi.org/10.14802/jmd.13008
  • 18,324 View
  • 74 Download
  • 7 Crossref
AbstractAbstract PDF

Amantadine is commonly used for Parkinsonism. However amantadine can induce adverse corneal reaction. Here we report a patient with primary progressive freezing of gait who had severe corneal edema associated with amantadine, which was reversible after discontinuation of the amantadine. This report alerts neurologists for this reversible but potentially critical corneal edema in patients with Parkinsonism who are receiving amantadine.

Citations

Citations to this article as recorded by  
  • Amantadine-induced corneal edema: A case and literature review
    Antony Raharja, Wessam Mina, Zahra Ashena
    American Journal of Ophthalmology Case Reports.2023; 32: 101881.     CrossRef
  • Experience of diagnosis and managements for patients with primary progressive freezing of gait
    Li-Li Zhang, Ya-Jie Zhao, Liang Zhang, Xiao-Ping Wang
    Journal of Neurorestoratology.2022; : 100039.     CrossRef
  • Toxicity of amantadine hydrochloride on cultured bovine cornea endothelial cells
    Po-Yen Lee, Yu-Hung Lai, Po-Len Liu, Ching-Chih Liu, Chia-Cheng Su, Fang-Yen Chiu, Wei-Chung Cheng, Shiuh-Liang Hsu, Kai-Chun Cheng, Li-Yi Chiu, Tzu-En Kao, Chia-Ching Lin, Yo-Chen Chang, Shu-Chi Wang, Chia-Yang Li
    Scientific Reports.2021;[Epub]     CrossRef
  • Efficacy and safety of amantadine for the treatment of l-DOPA-induced dyskinesia
    Santiago Perez-Lloret, Olivier Rascol
    Journal of Neural Transmission.2018; 125(8): 1237.     CrossRef
  • Ocular and visual disorders in Parkinson's disease: Common but frequently overlooked
    Merel S. Ekker, Sabine Janssen, Klaus Seppi, Werner Poewe, Nienke M. de Vries, Thomas Theelen, Jorik Nonnekes, Bastiaan R. Bloem
    Parkinsonism & Related Disorders.2017; 40: 1.     CrossRef
  • Parkinson’s disease between internal medicine and neurology
    Ilona Csoti, Wolfgang H. Jost, Heinz Reichmann
    Journal of Neural Transmission.2016; 123(1): 3.     CrossRef
  • Amantadine Use as a Risk Factor for Corneal Edema: A Nationwide Cohort Study in Taiwan
    Po Yen Lee, Hung Pin Tu, Chang Ping Lin, Cheng Hsien Chang, Kai Chun Cheng, Chia Ching Lin, Shiuh Liang Hsu
    American Journal of Ophthalmology.2016; 171: 122.     CrossRef

JMD : Journal of Movement Disorders